Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1 -Amplified Breast Cancer
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Chaofan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Moderni…. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Design, Antineoplastic Agents, Cell Proliferation. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Changjiang Scholar Program, Ministry of Education, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
CCNE1 amplification occurs in breast cancer and currently lacks effective therapies. PKMYT1 as a synthetic lethal target for CCNE1 amplification holds promise for the treatment of CCNE1-amplified breast cancer. Herein, we discover a series of 2-amino-[1,1'-biphenyl]-3-carboxamide derivatives as potent and selective PKMYT1 inhibitors using structure-based drug design. The representative compound 8ma exhibited excellent potency against PKMYT1, while sparing WEE1. It also suppressed proliferation of the CCNE1-amplified HCC1569 breast cancer cell line and showed synergistic cytotoxicity in combination with gemcitabine. PKMYT1 X-ray cocrystallography confirmed that introduction of key binding interactions between the inhibitors and residues Asp251 and Tyr121 of PKMYT1 greatly enhanced the potency and selectivity of the compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education,…
- Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, China.
- Department of Hematology, Guangdong Second Provincial General Hospital, Jinan University, Guangzhou 510632, China.
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
- Division of Antitumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
ORCID-Profile: Xiaoyun Lu
Förderung
- Changjiang Scholar Program, Ministry of Education
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- Opening Project of Guangdong Provincial Key Laboratory of New Drug Design and Evaluation
Zitieren
APA
Wang, C., Fang, Y., Zhou, Z., Liu, Z., Feng, F., Wan, X., Li, Y., Liu, S., Ding, J., Zhang, Z. M., Xie, H., & Lu, X. (2024). Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1 -Amplified Breast Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01458
Vancouver
Wang C, Fang Y, Zhou Z, Liu Z, Feng F, Wan X, et al. Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1 -Amplified Breast Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01458
BibTeX
@article{Wang2024,
author = {Wang, Chaofan and Fang, Yan and Zhou, Ziqin and Liu, Zhuoheng and Feng, Fang and Wan, Xuan and Li, Yan and Liu, Shuang and Ding, Jian and Zhang, Zhi-Min and Xie, Hua and Lu, Xiaoyun},
title = {Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1 -Amplified Breast Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01458}
}
EUVIMED